Mackenzie Financial’s Q32 Bio QTTB Stock Holding History

Mackenzie Financial’s Portfolio QTTB Stock Details QTTB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.58M	Buy	+246,304	New	+$1.17M	﹤0.01%	985

Other funds holding QTTB

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Mackenzie Financial's QTTB Position: Q1 2026 in Review

Mackenzie Financial opened a new position in Q32 Bio (QTTB) in Q1 2026: 246,304 shares worth $1.58M. The stake represents ﹤0.01% of the portfolio and ranks #985 among its holdings.

54 funds tracked by Wall St. Rank hold QTTB as of Q1 2026.

Mackenzie Financial held 246,304 shares of Q32 Bio worth $1.58M as of Q1 2026.
Q32 Bio was a new Mackenzie Financial position in Q1 2026.
Q32 Bio made up ﹤0.01% of Mackenzie Financial's portfolio in Q1 2026, its #985 holding.
54 funds tracked by Wall St. Rank held Q32 Bio as of Q1 2026.

Based on Mackenzie Financial's 13F filing for Q1 2026, filed 13 May 2026.